Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  European Journal of Cancer

• Publication date

  1996-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0959-8049(96)00110-4PMID 8869103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice

  2008cited by this paper
• Analysis and pharmacokinetics ofN-l-leucyldoxorubicin and metabolites in tissues of tumor-bearing BALB/c mice

  2004cited by this paper
• The role of biotransformation in anthracycline-induced cardiotoxicity in mice.

  1993cited by this paper
• Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines.

  1993cited by this paper
• Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.

  1992cited by this paper
• The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.

  1992cited by this paper
• Fully automated determination of a new anthracycline N-l-leucyldoxorubicin and six metabolites in plasma by high-performance liquid chromatography with on-line sample handling.

  1992cited by this paper
• DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin.

  1991cited by this paper
• The Nude Mouse in Oncology Research

  1991cited by this paper
• Sensitive method for the determination of daunorubicin and all its known metabolites in plasma and heart by high-performance liquid chromatography with fluorescence detection.

  1990cited by this paper
• Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer.

  1990cited by this paper
• Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the beta-adrenoceptor system and reactive oxygen species.

  1990cited by this paper
• Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

  1990cited by this paper
• Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.

  1989cited by this paper
• New method for the determination of doxorubicin, 4'-epidoxorubicin and all known metabolites in cardiac tissue.

  1988cited by this paper
• Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

  1988cited by this paper
• Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.

  1986cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells

  1982cited by this paper
• Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.

  1981cited by this paper
• The anthracycline antineoplastic drugs.

  1981cited by this paper
• Amino-acid and Dipeptide Derivatives of Daunorubicin .2. Cellular Pharmacology and Anti-tumor Activity On L1210 Leukemic-cells Invitro and Invivo

  1980cited by this paper
• Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion.

  1980cited by this paper
• Experimental evaluation of anthracycline analogs.

  1979cited by this paper
• Experimental evaluation of anthracycline analogs.

  1979cited by this paper
• A human cell line from a pleural effusion derived from a breast carcinoma.

  1973cited by this paper
• Production of Free Light Chains of Immunoglobulin by a Hematopoietic Cell Line Derived from a Patient with Multiple Myeloma.∗

  1967cited by this paper

• Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours.

  2010cites this paper
• Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines.

  2008cites this paper
• STRATEGIES TO TARGET CHEMOTHERAPEUTICS TO TUMORS

  2006cites this paper
• Durchflußzytometrische Untersuchungen zur zellulären Pharmakokinetik von freien und liposomal verkapseltem Daunorubicin

  2002cites this paper
• CPI-0004 Na , a New Extracellularly Tumor-Activated Prodrug of Doxorubicin : In Vivo Toxicity , Activity , and Tissue Distribution Confirm Tumor Cell Selectivity 1

  2002cites this paper
• CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

  2002cites this paper
• Prodrug strategies in cancer therapy.

  2001cites this paper
• Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts.

  1999cites this paper
• Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug.

  1999cites this paper
• The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.

  1998cites this paper
• The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.

  1998cites this paper
• Tumor‐selective Distribution of an Active Metabolite of the 9‐Aminoanthracycline Amrubicin

  1998cites this paper
• Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

  1998cites this paper